| C | |||||||
| Placebo | 0.06 (−1.55 to 1.67) | 1.22 (0.36 to 2.08) | |||||
| 1.75 (−1.68 to 5.19) |
Steroid Inj +Exe | 0.10 (−1.55 to 1.75) | 0.00 (−1.61 to 1.61) | ||||
| 1.43 (−0.46 to 3.32) | −0.32 (−3.20 to 2.55) | Steroid Inj | 0.18 (−1.51 to 1.88) | −0.22 (−1.91 to 1.48) | |||
| 0.06 (−1.55 to 1.67) | −1.69 (−5.49 to 2.10) | −1.37 (−3.86 to 1.12) | Orthoses | ||||
| 1.86 (−1.95 to 5.66) | 0.1 (−1.54 to 1.75) | 0.43 (−2.89 to 3.74) | 1.8 (−2.34 to 5.93) |
NSAID Inj +Exe | |||
| 1.61 (−0.92 to 4.14) | −0.14 (−2.47 to 2.19) | 0.18 (−1.51 to 1.87) | 1.55 (−1.45 to 4.55) | −0.25 (−3.10 to 2.61) | Exe | 0.15 (−1.54 to 1.84) | |
| 1.75 (−1.29 to 4.79) | 0 (−1.61 to 1.61) | 0.32 (−2.06 to 2.71) | 1.69 (−1.75 to 5.13) | −0.1 (−2.40 to 2.20) | 0.14 (−1.54 to 1.83) |
ESWT +Exe | |
| 1.22 (0.36 to 2.07) | −0.53 (−3.86 to 2.80) | −0.21 (−1.90 to 1.48) | 1.16 (−0.67 to 2.98) | −0.64 (−4.35 to 3.08) | −0.39 (−2.78 to 2.00) | −0.54 −3.45 to 2.38) | ESWT |
Summary estimates from the network meta-analysis are shown in lower left triangle, and summary estimates from pairwise meta-analysis (ie, direct evidence) in upper right triangle. Each cell shows a standardised mean difference (SMD), with a 95 % CI in parentheses . For any cell, a negative SMD favours the upper-left intervention, and a positive SMD favours the lower-right intervention. Significant results in bold text.
ESWT, extracorporeal shockwave therapy; ESWT+Exe, extracorporeal shockwave therapy combined with exercise; ESWT+Orthoses, extracorporeal shockwave therapy combined with orthoses; Exe, exercise; NSAID Inj+Exe, oral non-steroidal anti-inflammatory drug combined with exercise; Oral NSAID, oral non-steroidal anti-inflammatory drug; Orthoses, prefabricated or customised foot orthoses; Placebo, usual care/placebo; Steroid Inj, corticosteroid injection; Steroid Inj+Exe, corticosteroid injection combined with exercise.